ACOBIOM presents the clinical benefit of GemciTest® at ASCO 2021
The abstract presented at the 2021 ASCO Annual Conference is a study synthesis of the clinical performance of the CE-IVD molecular test to assess the gemcitabine response in advanced pancreatic cancer.